Copyright (c) 2006 Cancer Consultants. All rights reserved.Professional Cancer News from all disease categories.http://rss.cancerconsultants.com/ProFeed.aspx60http://professional.cancerconsultants.com/news.aspx?id=44268http://professional.cancerconsultants.com/news.aspx?id=44268Researchers from the Netherlands have reported that vaccination with synthetic long-peptides against human papillomavirus (HPV)-16 was effective in treating vulvar intraepithelial neoplasia (VIN). The details of this study were published in the November 5, 2009 issue of the New England Journal of Medicine.jmaxon@onco-ed.com (jenny maxon)Fri, 06 Nov 2009 12:16:59 GMThttp://professional.cancerconsultants.com/news.aspx?id=44267http://professional.cancerconsultants.com/news.aspx?id=44267Researchers from the M. D. Anderson Cancer Center and the University of Milan, Italy, have reported that women with Stage T1a,b, N0M0 HER2-positive breast cancers have a have a high recurrence rate without the administration of adjuvant chemotherapy or Herceptin® (trastuzumab). These data suggest that these women should be treated with Herceptin®-based adjuvant chemotherapy. The details of these two studies appeared in early online publications on November 2, 2009 in the Journal of Clinical Oncology.jmaxon@onco-ed.com (jenny maxon)Fri, 06 Nov 2009 12:03:25 GMThttp://professional.cancerconsultants.com/news.aspx?id=44266http://professional.cancerconsultants.com/news.aspx?id=44266Researchers affiliated with the NIH-AARP Diet and Health Study have reported that alcohol intake may reduce the risk of thyroid cancer. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.jmaxon@onco-ed.com (jenny maxon)Fri, 06 Nov 2009 10:36:49 GMThttp://professional.cancerconsultants.com/news.aspx?id=44262http://professional.cancerconsultants.com/news.aspx?id=44262Researchers from several U.S. and Spanish medical centers have reported that single-agent daily Sutent® (sunitinib) was associated with a 25% disease control rate in patients with previously treated advanced non–small cell lung cancer (NSCLC). The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.jmaxon@onco-ed.com (jenny maxon)Thu, 05 Nov 2009 10:25:55 GMThttp://professional.cancerconsultants.com/news.aspx?id=44261http://professional.cancerconsultants.com/news.aspx?id=44261Researchers from Japan have reported that dose-dense chemotherapy is effective for the treatment of patients with Stage IV thymoma. The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.jmaxon@onco-ed.com (jenny maxon)Thu, 05 Nov 2009 10:18:28 GMThttp://professional.cancerconsultants.com/news.aspx?id=44260http://professional.cancerconsultants.com/news.aspx?id=44260Researchers from the UK have reported that survivors of childhood cancer are 18 times more likely to develop thyroid cancer than the general population. The details of this study appeared in the November 15, 2009 issue of the International Journal of Cancer.jmaxon@onco-ed.com (jenny maxon)Thu, 05 Nov 2009 10:10:18 GMThttp://professional.cancerconsultants.com/news.aspx?id=44259http://professional.cancerconsultants.com/news.aspx?id=44259Researchers from Italy have reported that the addition of Rapamune® (sirolimus, rapamycin) to Gleevec® (imatinib) may improve disease control in patients with chordoma resistant to Gleevec. The details of this study appeared in the November 2009 issue of the Annals of Oncology.jmaxon@onco-ed.com (jenny maxon)Wed, 04 Nov 2009 15:39:03 GMThttp://professional.cancerconsultants.com/news.aspx?id=44258http://professional.cancerconsultants.com/news.aspx?id=44258Researchers from the M. D. Anderson Cancer Center have reported that the addition of low-dose interferon-alfa (IFN) to Nexavar® (sorafenib) did not improve survivals of patients with advanced renal cell carcinoma (RCC). The details of this study were published early online in Cancer on October 27. 2009.jmaxon@onco-ed.com (jenny maxon)Wed, 04 Nov 2009 15:26:41 GMThttp://professional.cancerconsultants.com/news.aspx?id=44257http://professional.cancerconsultants.com/news.aspx?id=44257Researchers from the Mayo Clinic have reported that patients with glioblastoma who are receiving enzyme-inducing anticonvulsant (EIAC) drugs may have improved outcomes compared with similar patients with glioblastoma not taking such drugs. The details of this study appeared in the October 13, 2009 issue of Neurology.jmaxon@onco-ed.com (jenny maxon)Wed, 04 Nov 2009 15:19:29 GMThttp://professional.cancerconsultants.com/news.aspx?id=44251http://professional.cancerconsultants.com/news.aspx?id=44251Researchers involved in the International Head and Neck Cancer Epidemiology Consortium have reported that smoking cessation for one to four years resulted in a 30% reduction in the risk of head and neck cancer. A benefit of cessation of alcohol drinking, however, was not observed until after 20 years or more. The details of this study appeared in an early online publication in the International Journal of Epidemiology on October 5, 2009.jmaxon@onco-ed.com (jenny maxon)Tue, 03 Nov 2009 14:57:34 GMT